Total
0
Shares
Emyria (ASX:EMD) - Managing Director, Dr Michael Winlo - The Market Herald
Managing Director, Dr Michael Winlo
Source: Emyria
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emyria (EMD) has launched a psychedelic-assisted therapy programme targeting treatment-resistant post-traumatic stress disorder
  • In partnership with Mind Medicine Australia, the EMDMA-001 programme is hoped to help evaluate the long-term safety and efficacy of MDMA-assisted psychotherapy
  • The phase two clinical trial for MDMA-assisted therapy is set to take place at Emyria's clinic in Melbourne once ethics approval has been granted, although it is unclear when this might take place
  • Emyria’s Managing Director, Dr Michael Winlo, said there is growing international interest in the promise of psychedelic-assisted therapies
  • Emyria shares are down 3.85 per cent trading at 25 cents

Emyria (EMD) has launched a psychedelic-assisted therapy programme targeting treatment-resistant post-traumatic stress disorder.

The clinical services company has partnered with Mind Medicine Australia to commence the EMDMA-001 programme in a bid to help evaluate the long-term safety, efficacy and cost benefits of MDMA-assisted psychotherapy.

Pending ethics approval, EMDMA-001 will start with a phase two clinical trial for MDMA-assisted therapy at Emyria's clinic in Melbourne.

More broadly, the ASX-lister expects this first program to be an important first step towards delivering safe, accredited, cost-effective, scalable and evidence-based, psychedelic-assisted therapy services across Australia.

Emyria’s Managing Director, Dr Michael Winlo, said there is growing international interest in the promise of psychedelic-assisted therapies.

"However, the care model and the drug intervention are intrinsically linked. This means any treatment will require a properly prepared and equipped clinical service" he explained.

"Our goal is to build a unique clinical database that we hope can help optimise
the development of existing and novel treatments while also allowing Emyria
and our partner, Mind Medicine Australia to become the trusted and accredited
clinical service of choice," he commented.

A cohort of psychotherapists are expected to graduate with Mind Medicine Australia’s certificate in psychedelic-assisted therapy training program end of this month, although a start date for the programme is yet to be adivsed.

Emyria shares are down 3.85 per cent trading at 25 cents at 11:41 am AEST.

EMD by the numbers
More From The Market Herald
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) signs COVID-19 test manufacturing contract

AnteoTech (ADO) has finalised and signed a contract manufacturing agreement with Spanish manufacturer, Operon.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito - The Market Herald

" Botanix Pharmaceuticals (ASX:BOT) receives encouraging results from canine study

Botanix Pharmaceuticals (BOT) says it has received encouraging results from a small pilot study of its synthetic CBD treatment in canines with atopic
Healthia (ASX:HLA) to purchase The Eyecare Place

" Healthia (ASX:HLA) to purchase The Eyecare Place

Healthia (HLA) has entered into agreements to purchase The Eyecare Place, an optical store located in Abbotsford, Victoria.
Avita Therapeutics (ASX:AVH) - CEO, Dr Michael Perry - The Market Herald

" Avita Medical (ASX:AVH) reports solid revenue growth over March quarter

Avita Medical (AVH) reported a 126-per-cent revenue increase and steady growth in procedural volumes in its review of the March quarter.